Here, the authors show that AAV-delivered CasRx to reduce the expression of Rock1 and Rock2 as well as Aqp1 and Adrb2 can significantly reduce intraocular pressure, ultimately delaying glaucoma progression in mice. Here, AQP1 is linked to glaucoma.